Functionally Guided Retinal Protective Therapy for Dry Age-Related Macular and Inherited Retinal Degenerations: A Pilot Study METHODS
|
|
- Camron Crawford
- 6 years ago
- Views:
Transcription
1 Retina Functionally Guided Retinal Protective Therapy for Dry Age-Related Macular and Inherited Retinal Degenerations: A Pilot Study Jeffrey K. Luttrull 1 3 and Benjamin W. L. Margolis Private Practice, Ventura, California, United States 2 Ojai Retinal Technologies, LLC, Ojai, California, United States 3 EyEngineering, Inc., Ojai, California, United States 4 Santa Clara University, Dynamics and Control Systems Laboratory, Santa Clara, California, United States Correspondence: Jeffrey K. Luttrull, 3160 Telegraph Road, Suite 230, Ventura, CA 93003, USA; jkluttrull@gmail.com. Submitted: September 11, 2015 Accepted: November 30, 2015 Citation: Luttrull JK, Margolis BWL. Functionally guided retinal protective therapy for dry age-related macular and inherited retinal degenerations: a pilot study. Invest Ophthalmol Vis Sci. 2016;57: DOI: / iovs PURPOSE. To review the results of retinal function testing in eyes undergoing panmacular subthreshold diode micropulse laser (SDM) prophylaxis for chronic progressive retinal disease. METHODS. The records of all patients undergoing prophylactic panmacular SDM for high-risk age-related macular degeneration (AMD) and inherited photoreceptor degenerations (IRDs) examined by pattern electroretinography (PERG), automated microperimetry (AMP), and Central Vision Analyzer (CVA) testing before and after treatment were reviewed. RESULTS. A total of 158 consecutive eyes of 108 patients with AMD and 10 consecutive eyes of 8 patients with IRDs, evaluated both before and after SDM by PERG, were eligible for study. The IRD diagnoses included rod cone degeneration (four eyes), cone rod degeneration (three eyes), and Stargardt s disease (three eyes). In AMD, AMP was performed in 40 consecutive eyes, and CVA in the subsequent 73 consecutive eyes concurrent with PERG. The SDM treatment consisted of 1800 to 3000 confluent spots throughout the retina circumscribed by the major vascular arcades, including the fovea ( panmacular ). Testing was performed 1 week before and by 1 month after treatment. Results indicated that 149/168 eyes were improved by primary PERG measures: 139/158 eyes with AMD by PERG lowcontrast scan Magnitude D (MagD)(lV)/Magnitude (Mag)(lV) ratios (P ¼ ) and 10/10 eyes with IRDs by 24 0 concentric ring scan MagD(lV)/Mag(lV) ratios (P ¼ 0.002). Snellen visual acuity (VA) was unchanged, but macular sensitivity by AMP (P ¼ ) and mesopic contrast VA by CVA (P ¼ 0.006) were improved. There were no adverse treatment effects. CONCLUSIONS. Our findings suggest a role for SDM as retinal protective therapy in chronic progressive retinal diseases. Pattern electroretinography enables (early, preventive) functionally guided, rather than (late, therapeutic) image-guided, disease management. Keywords: laser, macula, pattern electroretinogram, microperimetry, age-related macular degeneration, retinitis pigmentosa, prophylaxis, retinal protection, retinal function testing, functionally guided disease management, prevention, central vision analyzer, contrast sensitivity The complications of chronic progressive retinal diseases, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD), constitute major causes of visual loss worldwide. 1 Currently, retinal imaging and visual acuity (VA) testing guide management. 2 As end-organ structural damage and vision loss are late disease manifestations, treatment instituted at this point must be intensive, often prolonged and expensive, frequently failing to improve VA, and rarely restoring normal vision. 3 Subthreshold diode micropulse laser (SDM) has been shown to be effective treatment for a number of retinal disorders without adverse treatment effects By virtue of its safety and effectiveness, SDM has been proposed as preventive treatment for DR. 10 Recently, the Reset to Default hypothesis for SDM action has been proposed. 12 Reset Theory suggests SDM might protect the retina and slow progression of many chronic progressive retinal diseases. 11,12 On the basis of morphologic data suggesting slowing of AMD progression following SDM (Luttrull JK, unpublished data, 2012), 15 years of clinical experience with SDM, the concepts of Reset Theory, and the absence of adverse treatment effects, SDM was offered in a retinal practice (JKL) as prophylaxis/ retinal protection for high-risk AMD and inherited retinal degenerations (IRDs). Herein we report the results of retinal and visual function testing in a group of patients evaluated before and after SDM prophylaxis by pattern electroretinography (PERG), automated microperimetry (AMP), and Central Vision Analyzer (CVA) testing. METHODS This study adhered to the tenets of the Declaration of Helsinki and was approved by an investigational review board (Western IRB). The records of all patients in a retina subspecialty practice iovs.arvojournals.org j ISSN: This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 266 who were receiving SDM prophylaxis for high-risk AMD (defined by the presence of multiple large, diffuse, or bilateral macular drusen; macular pigment disturbance; extrafoveal or subfoveal geographic pigment atrophy; and/or choroidal neovascularization in the fellow eye) and IRDs, tested by PERG before and after SDM, were reviewed. In many eyes with AMD, additional visual function testing using AMP and CVA was done as well. Exclusionary criteria included other obfuscating ocular disease including epiretinal membrane or prior membrane peeling; DR; macular edema (except in retinitis pigmentosa); current or prior macular retinal vascular occlusion; prior macular choroidal neovascular membrane (CNVM); optic atrophy or advanced glaucomatous nerve damage; poor PERG test quality and/or reliability indicated by poor electrical conductivity or excessive (five or more) testing artifacts; subfoveal CNVM in the treated eye; active CNVM in the fellow eye requiring anti-vegf treatment within 1 month before SDM treatment, or between the time of SDM treatment and postoperative testing; and loss to follow-up before postoperative testing. Testing was performed within 1 week before SDM treatment, and within 1 month after treatment. As the setting for this pilot study was a solo private clinical retinal practice, the choice of testing modalities used reflected available technology, not necessarily ideal technology. Pattern Electroretinography Testing Pattern electroretinography was performed by using standard protocols of a commercially available system (Diopsys Nova- ERG; Diopsys Corp., Pine Brook, NJ, USA) according to International Society for Clinical Electrophysiology of Vision standards. 13 Both eyes were tested simultaneously and recorded individually, undilated, and refracted for a 60-cm testing distance. For all visual stimuli, a luminance pattern occupying a 258 visual field was presented with a luminance reversal rate of 15 Hz. For IRDs, a PERG concentric ring visual stimulus optimized for analyzing peripheral retinal sensitivity was used, presenting with a circle of 1 luminance and an outer ring with the contrasting luminance. The concentric ring stimulus used two subclasses of stimuli with an inner circle occupying a visual field of 168 and 248. The concentric ring stimuli used a mean luminance of cd/m 2 with a contrast of 100%. For AMD, in addition to the CR scans, contrast sensitivity (CS) stimuli were used, presenting a checkerboard -like grid of cells, alternating luminance levels, recording a highcontrast (HC) test with a mean luminance of 112 cd/m 2 and a contrast of 85%, and a low-contrast (LC) test with a mean luminance of cd/m 2 and a contrast of 75%. Patient and equipment preparation were carried out according to Diopsys guidelines. Signal acquisition and analysis followed a standard glaucoma screening protocol. 14 Test indices available for analysis included Magnitude D (MagD[lV]), Magnitude (lv) (Mag[lV]), and the MagD(lV)/Mag(lV) ratio. Magnitude D is the frequency response of the time-domain averaged signal in microvolts (lv). Inner retinal and/or ganglion cell dysfunction cause signal latencies resulting in magnitude and phase variability that reduce MagD(lV) by phase cancelation. Magnitude (lv) measures the frequency response of the total signal in microvolts (lv). Magnitude (lv) reflects the signal strength and electrode impedance of the individual test sessions, as well as a gross measure of inner retina and ganglion function. The MagD(lV)/Mag(lV) ratio thus provides a measure of patient response normalized to that particular test s electrical quality. In the healthy eye, MagD(lV) should roughly equal Mag(lV). Thus, the closer MagD(lV)/Mag(lV) is to unity, the more normal the macular function. Automated Microperimetry Testing Automated microperimetry (MAIA; Centervue, Inc., Fremont, CA, USA) testing was performed according to manufacturer recommendations. Following pupillary dilation, the patient was seated at the MAIA instrument with the head positioned and aligned to the testing screen. The patient was asked to maintain fixation on the fixation target and to signal notice of light points appearing on the instrument screen, projected at various thresholds and locations within the macular region, by depressing a hand-held button. Data thus recorded included percentage-reduced thresholds, average threshold, and percent initial and final fixation preferences (P1 and P2). Central Vision Analyzer Testing Central Vision Analyzer was performed in accordance with manufacturer guidelines (Visoptics, Mechanicsberg, PA, USA). The CVA is an FDA-approved measure of visual acuity. A thresholding algorithm is used to dynamically determine logmar central VA at six different levels of contrast under mesopic testing conditions, ranging from 99% to 35%, and simulating real-world visual demands, using an interactive computer interface. Each eye was tested undilated and best corrected. Subthreshold Diode Micropulse Laser Treatment Following informed consent and pupillary dilation, topical proparacaine was applied to the cornea. A Mainster macular contact lens (magnification factor 31.05; Ocular Instruments, Mentor, OH, USA) was placed on the cornea with the aid of viscoelastic. Under minimum slit-lamp illumination, the entire posterior retina circumscribed by the major vascular arcades was painted with 1800 to 3000 confluent spot applications of SDM ( panmacular treatment). The laser parameters used were 810-nm wavelength, 200-lm aerial spot size, 5% duty cycle; and 1.4-W power and 0.15-second duration (Oculight SLx; Iris Medical/Iridex Corp., Mountain View, CA, USA). Statistical Analysis All data was de-identified before statistical analysis. All analyses were performed by using linear mixed models predicting the measure, with an indicator for time as a covariate, adjusting for left or right eye, and including a random patient intercept to correct for possible intereye correlation. Finally, univariate linear mixed models, predicting the difference (post- minus pretreatment) with pretreatment value as covariate, were performed. The coefficients and P values from six such models were compared. Definitions In the following, macular function and retinal function refer to the physiology and electrophysiology of the retina. In contrast, visual function is used to refer to measurements such as VA, visual fields, and CS. RESULTS In all, 220 eyes of 166 patients undergoing panmacular SDM prophylaxis for high-risk AMD and IRDs, between June 2012 and August 2015, were identified. These included 210 eyes of 158 patients treated for AMD; and 10 eyes of 8 patients treated for IRDs. Of these, 158 consecutive eyes of 108 patients with AMD, and 10 consecutive eyes of 8 patients with IRDs were evaluated before and after SDM by PERG and thus eligible for
3 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 267 TABLE 1. Comparison of Various Measured Values (Post- Minus Pretreatment), PERG Contrast Sensitivity Test Eyes, for High-Risk AMD in Response to Panmacular SDM Laser Retinal Protective Therapy Variable Mean (SD) Median (IQR) P Value MagD(lV)/Mag(lV) ratio, high contrast 0.05 (0.19) 0.04 ( 0.07, 0.17) 0.09 MagD(lV)/Mag(lV) ratio, low contrast 0.08 (0.17) 0.08 (0.00, 0.17) MagD(lV) measure, high contrast 0.05 (0.32) 0.05 ( 0.17, 0.26) 0.37 MagD(lV) measure, low contrast 0.08 (0.25) 0.07 ( 0.06, 0.21) 0.02 Mag(lV) measure, high contrast 0.04 (0.34) 0.04 ( 0.23, 0.14) 0.42 Mag(lV) measure, low contrast 0.03 (0.33) 0.01 ( 0.19, 0.17) 0.55 The table shows the comparisons of interest for the PERG contrast sensitivity test data set. Each row shows the difference (post- minus pretreatment) in MagD(lV)/Mag(lV) ratio, MagD(lV) measure, or Mag(lV) measure at the two contrast options. To test whether the mean difference is different from zero, linear mixed models predicting the measure were used, with an indicator for time as a covariate, also adjusting for left or right eye. The P values are those associated with the time (pre versus post) regression coefficient. A significant P value indicates that the mean difference is significantly different from zero. The table shows that MagD(lV)/Mag(lV) ratio, low contrast, as well as MagD(lV) measure, low contrast, are significantly higher post treatment than pre treatment (positive values indicate higher posttreatment values, negative values indicate higher pretreatment values). This method accounts for intereye correlation. IQR, interquartile range. study. The IRD diagnoses included rod cone degeneration (four eyes), cone rod degeneration (three eyes), and Stargardt s disease (three eyes). Fifty-two eyes with AMD were treated before the beginning of PERG testing and thus ineligible for study. In the eligible AMD group, 25 patients were treated bilaterally. In the remainder, the fellow eye was excluded. The most common reasons for fellow eye exclusion in the AMD group were inactive CVNM or disciform scarring, epiretinal membrane, or current or prior retinal vascular occlusion. In the IRD group, the fellow eye of two patients was blind. Four patients with IRDs elected initial treatment in one eye only. Visual function testing was performed in 113 consecutive AMD eyes concurrently with PERG, including AMP in 40 consecutive eyes, and CVA testing in the subsequent 73 consecutive eyes. Overall, 149/168 eyes were improved by PERG after SDM. Snellen VAs, ranging from 20/20 to count fingers preoperatively, were unchanged (P ¼ 0.75, SD pre- versus postoperative ¼ 0.016). Patients with geographic atrophy frequently reported prompt subjective lightening or disappearance of their prior central scotoma. There were no adverse treatment effects, such as treatment-associated visual loss, or evidence of laser-induced retinal damage by clinical examination, spectraldomain optical coherence tomography, or fundus photography (Figs. 1 3). Of 158 eyes with high-risk dry AMD, 139 were improved by PERG after SDM. Post SDM, CS HC MagD(lV)/Mag(lV) ratios were not significantly improved (P ¼ 0.09). However, CS LC MagD(lV)/Mag(lV) ratios (P ¼ ) and CS LC MagD(lV) amplitudes (P ¼ 0.02) were significantly improved (Figs. 1 4; Tables 1, 2). Of 10 eyes with IRDs, 10 improved by PERG after SDM. Concentric ring 168 testing was not improved (P ¼ 0.19), but CR 248 MagD(lV)/Mag(lV) ratios (P ¼ 0.002) and MagD(lV) amplitudes (P ¼ 0.006) were both improved (Fig. 5; Table 3). In AMD, of the preoperative AMP measures, only the average thresholds were improved after SDM (P ¼ ). Central Vision Analyzer testing showed significant improvements in VA for all six levels of contrast, from 99% to 35% (P values: ; Tables 4, 5). Linear regression analyses revealed significant negative correlations for all testing measures in both AMD and IRDs, indicating that the worse the preoperative measure, the greater the likelihood of postoperative improvement (Fig. 6; Table 6). At the time of writing, 28/33 eyes improved by PERG at 1- month post SDM remained improved by PERG at 6 to 9 months post SDM. DISCUSSION Any treatment that improves retinal function, and thus health, should also reduce disease severity, progression, untoward events, and visual loss. 15,16 In this study, we found that panmacular SDM improved retinal and visual function in dry AMD and IRDs without adverse treatment effects. Recently, the mechanism of retinal laser treatment has been proposed and its clinical behavior described in Reset to Default Theory. 12 We believe the results of this study are supportive of Reset Theory. Fundamental to Reset Theory are certain predictions. First, SDM treatment should produce prompt improvement in retinal function. 4 Second, SDM treatment should be without any adverse effect by any measure. 4,9 Third, SDM treatment should produce diseasespecific benefits in a wide variety of disorders, including most, if not all, chronic progressive retinal disorders, regardless of eetiology. 5,12 Fourth, SDM treatment should be pathoselective, improving dysfunctional tissue while having negligible effect on normal tissue. Thus, the more dysfunction present, the more measured improvement anticipated after treatment. 12 Fifth, SDM treatment-induced improvements in retinal function, or retinal protection, might wear off, needing periodic retreatments to maintain maximum clinical benefits. 11,12,17 Our study did not address the final prediction. However, we found that PERG may be useful for monitoring retinal function and preventive treatment responses, and it can be complemented by AMP and CVA testing. Regarding the first four claims, our findings support Reset Theory. Because there are few similarities between AMD and various IRDs, we report both to examine Reset Theory s prediction of SDM as a nonspecific trigger of disease-specific retinal repair. Reset Theory predicts both the positive treatment response across these different diagnoses, as well as the distinctive PERG responses observed in this study. Pattern electroretinography was introduced in 1964 by Riggs and associates. 18 Unlike ganzfield and focal electroretinography (ERG) that use flash stimuli to measure photoreceptor function, PERG uses projected temporally and spatially alternating patterned stimuli of constant illumination to generate a neuroretinal electrophysiologic response that is either a series of transient responses at slow reversal rates (<5 Hz), or a periodic steady-state response at faster reversal rates (>5 Hz). Originally thought to be simply an alternate form of ERG, PERG was recognized in the 1980s to arise from different sources, principally the inner retina and ganglion cell layer. 19 Pattern electroretinography has since been shown to be an objective, sensitive, and highly reproducible indicator of both macular and ganglion cell function. Performed in a single
4 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 268 FIGURE 1. Infrared (left) and fundus autofluorescence photographs (right) of right eye (top) and left eye (bottom) of a patient with AMD and geographic pigmentary atrophy 3 months after panmacular SDM treatment. Visual acuity of right eye before and after treatment, 20/100. Visual acuity of left eye before treatment, 20/70; after treatment, 20/50. Note absence of retinal laser lesions. center by experienced personnel, PERG has been shown to be reliable and highly repeatable As ours was a clinic-based pilot study, the diagnostic technologies we used are not necessarily ideal, but simply the technologies available to us. Of these, we found PERG the most informative. In the absence of optic nerve disease, PERG responses reflect macular function, measured at the inner retina and ganglion cell layer and reflecting input from the outer retina Pattern electroretinography is a sensitive test that can be difficult to perform well. 20 However, as noted above (Odom et al. 20 ), we also found that PERG done in a single location on the same machine by the same technician with the same technique can provide useful and consistent information. 20,21 As one of the earliest detectors of ganglion cell dysfunction, PERG is a sensitive predictor of glaucoma and progression, anticipating visual field loss by years, and improves following
5 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 269 FIGURE 2. Spectral-domain optical coherence tomography of eye with high-risk AMD before (above) and after (below) panmacular SDM retinal protective therapy. Note absence of retinal laser damage. normalization of intraocular pressure As a measure of macular function, PERG is reduced by AMD and other maculopathies and responsive to therapies for neovascular AMD. 25 However, the result of any testing method will vary in a particular patient over time, even in the absence of clinical change. At times, such variability may make interpretation of test results difficult or even misleading. This is also true for PERG, but less so than for tests requiring higher levels of patient cooperation, such as visual field testing. Thus, it may be difficult to make a judgment on a particular patient, on a particular day, based on a single test result, particularly in a novel test application. Constrained by economic considerations and patient fatigue, serial testing in clinical practice for result averaging is impractical. Thus, it is reassuring that the SDM treatment effects, detected most sensitively by PERG, were consistent, robust, highly significant, and appear to be sustained for at least 6 months postoperatively in most patients. We expect that prospective trials will reveal the FIGURE 3. Posttreatment fundus autofluoresence photograph of eye with age-related geographic atrophy, after panmacular SDM retinal protective therapy. Note absence of laser lesions. Visual acuity before treatment, 20/200; after treatment, 20/60. duration of the typical treatment response and indicate the ideal times to consider retreatment in order to maintain the maximum treatment benefits, reducing reliance on individual episodic testing results. Of note is that many treated AMD eyes, and both eyes with Stargardt s disease, had extensive macular geographic atrophy included in confluent panmacular SDM treatment (Fig. 1). These eyes had the poorest preoperative testing responses. However, linear regression analysis showed that these eyes also had the greatest improvements after treatment, by all measures. While a discussion of the implications of this observation is beyond the scope of this article, it is clear that TABLE 2. Comparison of Various Measured Values (Post- Minus Pretreatment), Concentric Ring Scan Eyes With High-Risk AMD Treated With Panmacular SDM Laser Retinal Protective Therapy Variable Mean (SD) Median (IQR) P Value MagD(lV)/Mag(lV) ratio, (0.21) 0.01 ( 0.09, 0.12) 0.44 MagD(lV)/Mag(lV) ratio, (0.22) 0.07 ( 0.10, 0.20) 0.07 MagD(lV) measure, (0.38) 0.02 ( 0.20, 0.23) 0.52 MagD(lV) measure, (0.26) 0.03 ( 0.13, 0.21) 0.27 Mag(lV) measure, (0.36) 0.00 ( 0.18, 0.20) 0.86 Mag(lV) measure, (0.36) 0.03 ( 0.21, 0.15) 0.41 The table shows the comparisons of interest for the PERG concentric ring test data set. Each row shows the difference (first post- minus pretreatment) in MagD(lV)/Mag(lV) ratio, MagD(lV) measure, or Mag(lV) measure at 248 and 168. To test whether the mean difference is different from zero, linear mixed models predicting the measure were used, with an indicator for time as a covariate, also adjusting for left or right eye. The P values are those associated with the time (pre versus post) regression coefficient. A significant P value indicates that the mean difference is significantly different from zero. The table shows that all comparisons are not statistically significant. This method accounts for intereye correlation.
6 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 270 FIGURE 4. Scatterplots of AMD PERG high- and low-contrast MagD(lV)/Mag(lV) ratios before and after SDM treatment. functional tissue responsive to therapy remains within areas of geographic atrophy (Figs. 1, 2, 6; Table 6). Paralleling the PERG responses, we found that VA measured by CVA testing significantly improved in AMD eyes, along with macular sensitivity measured by AMP. Improvements in visual function captured by AMP and CVA are important, indicating a benefit from SDM treatment in the overall quality of visual function that is not revealed by conventional chart VA testing. As loss of CS is the earliest visual abnormality in AMD, and thus a sensitive indicator of disease, it is notable that the improvements in dry AMD following SDM were reflected most by measures of CS. The SDM-elicited improvements in visual function, particularly measured by CVA testing under mesopic conditions, suggest a practical benefit for patients with dry
7 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 271 TABLE 3. Comparison of Various Measured Values (Post- Minus Pretreatment) for Eyes With Inherited Retinal Degenerations Treated by Panmacular SDM Retinal Protective Therapy Tested by PERG Concentric Ring Scans All Eyes, N ¼ 15 Treated Eyes, N ¼ 9 Untreated Eyes, N ¼ 6 P Value* P Value* Mean (SD) Median (IQR) P Value* Mean (SD) Median (IQR) Mean (SD) Median (IQR) Variable MagD(lV)/Mag(lV) ratio, (0.21) 0.05 ( 0.01, 0.19) (0.18) 0.18 (0.08, 0.25) (0.13) 0.03 ( 0.23, 0.05) 0.56 MagD(lV)/Mag(lV) ratio, (0.19) 0.07 ( 0.01, 0.19) (0.24) 0.11 (0.00, 0.33) (0.09) 0.06 ( 0.01, 0.14) 0.22 MagD(lV) measure, (0.22) 0.11 ( 0.07, 0.22) (0.21) 0.14 (0.11, 0.24) (0.16) 0.04 ( 0.18, 0.04) 0.44 MagD(lV) measure, (0.20) 0.07 ( 0.02, 0.22) (0.24) 0.10 ( 0.02, 0.22) (0.15) 0.06 (0.02, 0.18) 0.22 The table shows the comparisons of interest for the IRD data set. Each row shows the difference (post- minus pretreatment) in MagD(lV)/Mag(lV) ratio or MagD(lV) measure, at the two degree options. Shown are the statistics for all eyes, treated eyes, and untreated eyes. Statistical significance was tested by using Wilcoxon signed rank sum tests owing to the small sample size and likely violation of the normality of these measures. The table shows that MagD(lV)/Mag(lV) ratio, 248 is significantly higher post treatment than pre treatment in treated eyes (P ¼ 0.004; positive values indicate higher posttreatment values, negative values indicate higher pretreatment values). Also, we see that MagD(lV), 248 is significantly higher post treatment than pre treatment in untreated eyes (P ¼ 0.01; positive values indicate higher posttreatment values, negative values indicate higher pretreatment values). The other comparisons are not statistically significant. * Wilcoxon signed rank sum test. TABLE 4. Summary of Calculated Difference (Post- Minus Pretreatment) for Eyes With Age-Related and Inherited Retinal Degenerations Treated With Panmacular SDM Retinal Protective Therapy, AMP Eyes Accounting for Possible Intereye Correlation Variable Mean (SD) Median (IQR) P Value Reduced threshold (N miss ¼ 8) 2.72 (16.98) 0.00 ( 6.75, 6.75) Average threshold (28.02) 0.35 ( 0.85, 2.65) P (33.30) 0.50 ( 12.00, 7.50) P (21.04) 0.00 ( 5.50, 5.00) The table shows the comparisons of interest for the AMP data set. Each row shows the difference (follow-up minus pre operation) in reduced and average threshold as well as P1 and P2. To test whether the mean difference is different from zero, linear mixed models predicting the measure were used, with an indicator for time (preoperative versus follow-up) as a covariate, also adjusting for left or right eye. The P values are those associated with the time (preoperative versus follow-up) regression coefficient. A significant P value indicates that the mean difference is significantly different from zero. Only average threshold is significantly different preoperatively versus follow-up. N miss, number of missing data points for the reduced threshold measure; P1, initial fixation preference; P2, final fixation preference. AMD, who often note difficulty reading and functioning in lowlight and low-contrast settings, common activities of daily living Identifying a benefit from prophylactic treatment of chronic progressive retinal diseases morphologically is inherently problematic. Abnormal retinal (physiologic) function precedes anatomic derangement and loss of visual function. It is initially asymptomatic and associated with normal retinal imaging. Abnormal visual function, by contrast, is generally symptomatic, resulting from anatomic derangements such as loss of photoreceptors, or the development of macular edema. Thus, reflecting advanced disease and end-organ damage detectable by retinal imaging, visual loss may be difficult to treat and is often irreversible. Likewise, retinal degeneration in chronic disease usually develops slowly, often over decades of retinal dysfunction, making morphologic detection of preventive treatment effects difficult, and then only after the fact. As current retinal disease management is predicated on the results of retinal imaging, treatment is necessarily offered late in the disease process. Treatment of advanced disease is most difficult and least rewarding, needing to be more potent, intensive, prolonged, usually more expensive, and still unlikely to restore normal VA. Interventions before visual loss and abnormalities detectable by retinal imaging thus offer the best prospect for preservation of normal visual function. Therefore, preventive treatments must necessarily be guided by retinal function testing rather than retinal imaging or VA testing. We call this functionally guided (disease) management (FGM). By allowing early diagnosis and disease monitoring before the onset of retinal anatomic changes, we expect FGM to improve visual outcomes when compared to current practices. High-density/low-intensity SDM was developed in 2000 and first reported in 2005 as effective treatment for diabetic macular edema without laser-induced retinal damage. 4 Subthreshold diode micropulse laser applies sublethal thermal laser stimulation selectively to the RPE and has been reported to be effective for a number of retinal disorders without adverse treatment effects. In addition to DME, these include severe nonproliferative and proliferative DR, branch retinal vein occlusion, and central serous chorioretinopathy. 4 10,12 Unlike conventional photocoagulation for DME, SDM improves macular sensitivity by AMP. 27 Based on these observations, the Reset to Default Theory of SDM action was proposed to
8 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 272 FIGURE 5. Scatterplots of IRD PERG 248 concentric ring MagD(lV)/Mag(lV) ratios and MagD(lV) amplitudes before and after SDM treatment. describe the clinical behavior of SDM. 12 Reset Theory suggests RPE heat-shock protein (HSP) activation as the principal therapeutic mechanism of SDM and all other forms of retinal laser treatment (other than cautery). 30 By triggering HSPmediated RPE repair, RPE function, and thus health, is improved, leading to normalization of RPE cytokine expression and retinal autoregulation. Although HSP activation has long been theorized as one possible mechanism of retinal laser treatment, Reset Theory suggests the primacy of this pathway (via SDM s elimination of prior models, which theorized benefits from retinal photocoagulation) and provides a framework for understanding the resultant clinical implications arising from this mechanism The power of any theory rests in its ability to predict. Reset Theory has successfully predicted the unprecedented observation that SDM could reverse drug tolerance in neovascular AMD. 12 Reset Theory also predicted the treatment responses in dry AMD and IRDs we report here.
9 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 273 TABLE 5. Summary of Calculated Difference (Post- Minus Pretreatment), Visual Acuity on LogMAR Scale Measured by the Central Visual Acuity Analyzer in Eyes With Age-Related and Inherited Retinal Degenerations Treated With Panmacular SDM Retinal Protective Therapy Variable N Mean (SD) Median (IQR) P Value 99% Contrast (0.511) ( 0.336, 0.114) % Contrast (0.488) ( 0.301, 0.107) % Contrast (0.458) ( 0.301, 0.067) % Contrast (0.444) ( 0.248, 0.097) % Contrast (0.370) ( 0.250, 0.058) % Contrast (0.416) ( 0.248, 0.105) 0.03 The table shows the difference (post- minus pretreatment) in logmar visual acuity at six levels of contrast measured under mesopic testing conditions. To test whether the mean difference is different from zero, linear mixed models predicting the visual acuity were used, with an indicator for time as a covariate, also adjusting for left or right eye. The table shows significant improvement at all contrast levels. This method accounts for intereye correlation. FIGURE 6. Scatterplots of the linear regression analysis of the dry AMD PERG MagD(lV)/Mag(lV) (top) and MagD(lV) (bottom) ratios. Note the negative slope, statistically significant in each, indicating that the worse the preoperative value, the greater the degree of postoperative improvement.
10 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 274 TABLE 6. Comparison of Various Measured Values (Post- Minus Pretreatment), of PERG Contrast Sensitivity Testing of Eyes With Dry Age-Related Macular Degeneration Variable Mean (SD) Median (IQR) P Value* MagD(lV)/Mag(lV) ratio, high contrast 0.04 (0.19) 0.05 ( 0.06, 0.14) MagD(lV)/Mag(lV) ratio, low contrast 0.11 (0.18) 0.11 (0.02, 0.21) < MagD(lV) measure, high contrast 0.03 (0.28) 0.06 ( 0.17, 0.24) MagD(lV) measure, low contrast 0.10 (0.25) 0.09 ( 0.04, 0.22) Mag(lV) measure, high contrast 0.07 (0.37) 0.05 ( 0.30, 0.12) Mag(lV) measure, low contrast 0.04 (0.36) 0.00 ( 0.24, 0.13) The table shows the post- minus pretreatment differences of various measures among the PERG contrast sensitivity testing of eyes with dry agerelated macular degeneration. Paired t-tests were performed to determine whether each measure differed significantly pre treatment versus post treatment. MagD(lV)/Mag(lV) ratio, high and low contrast, were both significantly (P ¼ 0.03 and P < , respectively) higher, on average, post treatment. MagD(lV), low contrast, was also significantly (P ¼ 0.006) higher post treatment. * Paired t-tests. In principle, improved retinal function and health, if maintained, should produce long-term benefits, reducing both the rate of disease progression and incidence of adverse events. Our findings support the Reset Theory suggestion that, as a nonspecific stimulus of disease-specific retinal repair, SDM may produce salutary effects in a number of unrelated chronic progressive retinopathies. Further study is needed to confirm our findings and will reveal whether such effects, which may be thought of as homeotrophic as they normalize tissue function, will lead to long-term clinical benefits in AMD and IRDs. Longer experience with SDM for complications of DR is encouraging in this regard 5,8 10,12 (Fig. 7). Primary immutable disease factors such as age, diabetes mellitus, or inherited genetic defects are not amenable to HSPmediated retinal repair. However, it is interesting to note that the presence of such abnormalities alone is generally insufficient to cause visual loss, as patients with chronic progressive retinopathies may enjoy normal or near-normal visual function for decades before developing clinical retinopathy and experiencing visual loss. This suggests that it may be secondary abnormalities, caused by the immutable defect, accumulating over time both upstream and downstream from the primary defect, that cause the cell death and anatomic derangement that result in visual loss. These secondary abnormalities are the ones most amenable to SDM-stimulated HSP-mediated repair. 5,9 12,16 By mitigating the effects of such secondary defects, retinal degeneration and visual loss might thus be delayed if not prevented. Only controlled long-term studies can determine if SDM retinal protective therapy will be helpful in this regard. However, before long-term treatment benefits can be hoped for, early improvements, such as those we reported here in dry AMD and IRDs, must be achieved. This study had limitations common to pilot studies. It reported a small group of patients from a single center receiving a novel treatment assessed in a novel way. The data were obtained by retrospective review of medical records developed in the course of clinical patient care, rather than through a controlled prospective experimental protocol. However, while the data were limited and imperfect, they are not uninformative or unimportant. 31 The primary outcome measure derives from a well-known, objective, and reproducible measure of macular function, PERG, and is echoed by measures of visual function including AMP and CVA. Consistent with 15 years of clinical experience and prior reports, we observed SDM to consistently, safely, and significantly improve retinal and visual function in chronic progressive retinal degenerations including dry AMD and IRDs. This suggests that SDM, as retinal protective therapy, followed by timely functionally guided retreatment, has the potential to slow disease progression and reduce complications and visual loss over time in these disorders. 32 As a prompt indicator of retinal treatment effects, PERG may be valuable as a surrogate indicator in the development of new retinal therapies. 33 Quick determination of whether or not a new treatment improves retinal function (and thus retinal health) may expedite identification of therapies with promise, and abandonment of FIGURE 7. Intravenous fundus fluorescein angiograms of eye with severe nonproliferative diabetic retinopathy before (left) and after (right) panretinal SDM. Note decreased micro- and macrovascular leakage, with reperfusion of local ischemia.
11 Functionally Guided Retinal Protective Therapy IOVS j January 2016 j Vol. 57 j No. 1 j 275 those without. These results may provide initial benchmarks. Further research is warranted. Acknowledgments The authors thank Taylor Blachley, MS, and David C. Musch, PhD, MPH, of the Department of Biostatistics, University of Michigan Medical School, for their assistance in the statistical analysis of study data; and Stephen H. Sinclair, MD, for his editorial assistance. The authors alone are responsible for the content and writing of the paper. Disclosure: J.K. Luttrull, None; B.W.L. Margolis, None References 1. Bourne RR, Stevens GA, White RA, et al.; Vision Loss Expert Group. Causes of vision loss worldwide, : a systematic analysis. Lancet Glob Health. 2013;1: Schachat AP, Thompson JT. Optical coherence tomography, fluorescein angiography, and the management of neovascular age-related macular degeneration. Ophthalmology. 2015;122: Schmidt-Erfurth U, Lang GE, Holz FG, et al.; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE Extension Study. Ophthalmology. 2014;121: Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol. 2005; 89: Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8: Koss MJ, Berger I, Koch FH. Subthreshold laser micropulse photocoagulation versus intravitreal injections of bevacizumab in the treatment of central serous chorioretinopathy. Eye. 2012;26: Roisman L, Magalhães FP, Lavinsky D, et al. Micropulse diode laser treatment for chronic central serous chorioretinopathy: a randomized pilot trial. Ophthalmic Surg Lasers Imaging Retina. 2013;44: Luttrull JK, Spink CJ, Musch DA. Subthreshold diode micropulse panretinal photocoagulation for proliferative diabetic retinopathy. Eye. 2008;22: Luttrull JK, Sramek C, Palanker D, et al. Long-term safety, highresolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina. 2012;32: Luttrull JK, Sinclair SH. Safety of transfoveal subthreshold diode micropulse laser (SDM) for fovea-involving diabetic macular edema in eyes with good visual acuity. Retina. 2014; 34: Sramek C, Mackanos M, Spitler R, et al. Non-damaging retinal phototherapy: dynamic range of heat shock protein expression. Invest Ophthalmol Vis Sci. 2011;52: Luttrull JK, Chang DB, Margolis BWL, Dorin G, Luttrull DK. Laser resensitization of medically unresponsive neovascular age-related macular degeneration: efficacy and implications. Retina. 2015;35: McCulloch DL, Marmor MF, Brigell MG, et al. ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol. 2015;130: Porciatti V, Ventura LM. Normative data for a user-friendly paradigm for pattern electroretinogram recording. Ophthalmology. 2004;111: Garrison FH. An Introduction to the History of Medicine. 4th ed. Philadelphia: W.B. Saunders Company; Scott IU, Jackson GR, Quillen DA, et al. Effect of doxycycline vs placebo on retinal function and diabetic retinopathy progression in patients with severe nonproliferative or nonhigh-risk proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2014;132: Sivaprasad S, Sandu R, Tandon A, et al. Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clin Experiment Ophthalmol. 2007;35: Riggs LA. Electroretinography. Vision Res. 1986;26: Arden GB, Vaegan, Hogg CR. Clinical and experimental evidence that the pattern electroretinogram (PERG) is generated in more proximal retinal layers than the focal electroretinogram (FERG). Ann N Y Acad Sci. 1982;388: Odom JV, Holder GE, Feghali JG, Cavender S. Pattern electroretinogram intrasession reliability: a two center comparison. Clin Vis Sci. 1992;7: Bowd C, Trafreshi A, Zangwill LA, et al. Repeatability of pattern electrogram measurements using a new paradigm optimized for glaucoma detection. J Glaucoma. 2009;18: Ventura LM, Feuer WJ, Porciatti V. Progressive loss of retinal ganglion cell function is hindered with IOP-lowering treatment in early glaucoma. Invest Ophthalmol Vis Sci. 2012;53: Banitt MR, Ventura LM, Feuer WJ, et al. Progressive loss of retinal ganglion cell function precedes structural loss by several years in glaucoma suspects. Invest Ophthalmol Vis Sci. 2013;54: Ventura LM, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction: a pilot study. Ophthalmology. 2005;112: Neveu MM, Tufail A, Dowler JG, Holder GE. A comparison of pattern and multifocal electroretinography in the evaluation of age-related macular degeneration and its treatment with photodynamic therapy. Doc Ophthalmol. 2006;113: Vujosevic S, Bottega E, Casciano M, et al. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified Early Treatment Diabetic Retinopathy Study laser photocoagulation. Retina. 2010;30: Wu Z, Ayton LN, Luu CD, Guymer RH. Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration. JAMA Ophthalmol. 2015;133: Gutstein W, Sinclair SH, Presti P, North RV. Interactive thresholding of central acuity under contrast and luminance conditions mimicking real world environments: 1, evaluation against LogMAR charts. J Comput Sci Syst Biol. 2015;8: Faria BM, Duman F, Zheng CX, et al. Evaluating contrast sensitivity in age-related macular degeneration using a novel computer-based test, the Spaeth/Richman contrast sensivity test. Retina. 2015;35: Kregel K. Invited review: heat shock proteins: modifying factors in physiological stress responses and acquired thermotolerance. J Appl Physiol. 2002;92: Van Teijlingen ER, Rennie AM, Hundley V, Graham W. The importance of conducting and reporting pilot studies: the example of the Scottish Births Survey. J Adv Nurs. 2001;34: Rothman K, Greenland S, Lash T, eds. Modern Epidemiology. 3rd ed. Riverwoods, IL: Lippincott Williams & Wilkins; Ellenberg SS. Surrogate endpoints. Br J Cancer. 1993;68:
LOW-INTENSITY/HIGH-DENSITY SUBTHRESHOLD DIODE MICROPULSE LASER FOR CENTRAL SEROUS CHORIORETINOPATHY
LOW-INTENSITY/HIGH-DENSITY SUBTHRESHOLD DIODE MICROPULSE LASER FOR CENTRAL SEROUS CHORIORETINOPATHY JEFFREY K. LUTTRULL, MD Purpose: To review the results of low-intensity/high-density subthreshold micropulse
More informationMulti-Modal Longitudinal Evaluation of Subthreshold Laser Lesions in Human Retina, Including Scanning Laser Ophthalmoscope-Adaptive Optics Imaging
EXPERIMENTAL SCIENCE Multi-Modal Longitudinal Evaluation of Subthreshold Laser Lesions in Human Retina, Including Scanning Laser Ophthalmoscope-Adaptive Optics Imaging Edward H. Wood, MD; Theodore Leng,
More informationSAFETY OF TRANSFOVEAL SUBTHRESHOLD DIODE MICROPULSE LASER FOR FOVEA-INVOLVING DIABETIC MACULAR EDEMA IN EYES WITH GOOD VISUAL ACUITY
SAFETY OF TRANSFOVEAL SUBTHRESHOLD DIODE MICROPULSE LASER FOR FOVEA-INVOLVING DIABETIC MACULAR EDEMA IN EYES WITH GOOD VISUAL ACUITY JEFFREY K. LUTTRULL, MD,* STEPHEN H. SINCLAIR, MD Purpose: To determine
More informationWe know diabetes is a common and growing problem as well as the leading cause
ebook A GAME-CHANGER IN DIABETIC RETINOPATHY Early diagnosis and management guidance using objective, functional vision testing. by STEVEN M. SILVERSTEIN, MD We know diabetes is a common and growing problem
More informationCase Report Increase in Central Retinal Edema after Subthreshold Diode Micropulse Laser Treatment of Chronic Central Serous Chorioretinopathy
Case Reports in Ophthalmological Medicine Volume 2015, Article ID 813414, 4 pages http://dx.doi.org/10.1155/2015/813414 Case Report Increase in Central Retinal Edema after Subthreshold Diode Micropulse
More informationIQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Fawwaz Al Mamoori* Medical Retina Department, Eye Specialty Hospital,
More informationTissue-Sparing MicroPulse Photocoagulation
Tissue-Sparing MicroPulse Photocoagulation What is MicroPulse? A technology that finely controls thermal elevation by: chopping a CW beam into a train of repetitive microsecond pulses allowing tissue to
More informationA Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders
Adv Ther (2017) 34:1528 1555 DOI 10.1007/s12325-017-0559-y REVIEW A Review of Subthreshold Micropulse Laser for Treatment of Macular Disorders Paula Scholz. Lebriz Altay. Sascha Fauser Received: March
More informationTherapy Quick Guide. Leading MicroPulse surgeons share tissue-sparing laser techniques for the treatment of retinal disorders and glaucoma
Therapy Quick Guide Leading MicroPulse surgeons share tissue-sparing laser techniques for the treatment of retinal disorders and glaucoma Become a member of the IRIDEX MicroPulse Forum. Learn more at iridex.com/micropulse
More informationEfficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration
Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD
More informationInternational Journal of Basic and Applied Physiology
Multifocal Electroretinography in Assessment Of Diseases Of Posterior Pole Of Retina JagdeepKaur S. Dani*, Mitesh M. Sinha**, Archana H. Patel**, Anju B. Mehta ***, Geeta B. Nair**** *Associate Professor,
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationWhat You Should Know About Acute Macular Neuroretinopathy
What You Should Know About Acute Macular Neuroretinopathy David J. Browning MD, PhD Chong Lee BS Acute macular neuroretinopathy is a condition characterized by the sudden, painless onset of paracentral
More informationDry AMD: the regulatory view
EMA Ophthalmology Workshop 2011 Dry AMD: the regulatory view Marco Coassin, MD PhD University of Rome Campus Bio-Medico - Italy In this presentation Personal views Previous scientific advices No currently
More informationOriginal Policy Date
MP 9.03.08 Photocoagulation of Macular Drusen Medical Policy Section Miscellaneous Policies Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
More informationClinical Trial Endpoints for Macular Diseases
Clinical Trial Endpoints for Macular Diseases Developed in collaboration Learning Objective Upon completion, participants should be able to: Summarize types of biomarkers of progression and treatment response
More informationVISUAL EVOKED POTENTIAL PATTERN ELECTRORETINOGRAM ASSESSMENT OF NEURO VISUAL FUNCTION. Lee Shettle, D.O. Lee Shettle Eye & Hearing
VISUAL EVOKED POTENTIAL PATTERN ELECTRORETINOGRAM ASSESSMENT OF NEURO VISUAL FUNCTION Lee Shettle, D.O. Lee Shettle Eye & Hearing Overview of VEP / PERG Why should I Use this Test? How does it work? Clinical
More informationElectrodiagnostics Alphabet Soup
Nathan Lighthizer, O.D., F.A.A.O Assistant Professor, NSUOCO Chief of Specialty Care Clinics Chief of Electrodiagnostics Clinic What is electrodiagnostics testing? Visual Pathway Basic Understanding VEP
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationRetina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014
Retina Conference Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Subjective CC/HPI: 64 year old Caucasian female referred by outside ophthalmologist
More informationIn office electrodiagnostics: what can it do for you
9/6/6 In office electrodiagnostics: what can it do for you Nathan Lighthizer, O.D., F.A.A.O Assistant Professor, NSUOCO Chief of Specialty Care Clinics Chief of Electrodiagnostics Clinic Course Outline/Objective
More informationFundus Autofluorescence. Jonathan A. Micieli, MD Valérie Biousse, MD
Fundus Autofluorescence Jonathan A. Micieli, MD Valérie Biousse, MD The retinal pigment epithelium (RPE) has many important functions including phagocytosis of the photoreceptor outer segments Cone Rod
More informationThe New Frontier of Microperimetry
Macular Integrity Assessment The New Frontier of Microperimetry Microperimetry is attracting our attention more and more as a method that is superior to standard automated perimetry for visual function
More informationOCCLUSIVE VASCULAR DISORDERS OF THE RETINA
OCCLUSIVE VASCULAR DISORDERS OF THE RETINA Learning outcomes By the end of this lecture the students would be able to Classify occlusive vascular disorders (OVD) of the retina. Correlate the clinical features
More informationClinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome
Hindawi Publishing Corporation Journal of Ophthalmology Volume 215, Article ID 62372, 5 pages http://dx.doi.org/1.1155/215/62372 Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationFacts About Diabetic Eye Disease
Facts About Diabetic Eye Disease Points to Remember 1. Diabetic eye disease comprises a group of eye conditions that affect people with diabetes. These conditions include diabetic retinopathy, diabetic
More informationThe New Frontier of Microperimetry
Macular Integrity Assessment The New Frontier of Microperimetry Index 4 Company Profile Microperimetry is attracting our attention more and more as a method that is superior to standard automated perimetry
More informationThe beneficial effects of focal photocoagulation for clinically
Retinal Function in Diabetic Macular Edema after Focal Laser Photocoagulation Vivienne C. Greenstein, 1 Haifan Chen, 1 Donald C. Hood, 2 Karen Holopigian, 1 William Seiple, 1 and Ronald E. Carr 1 PURPOSE.
More informationBrampton Hurontario Street Brampton, ON L6Y 0P6
Diabetic Retinopathy What is Diabetic Retinopathy Diabetic retinopathy is one of the leading causes of blindness world-wide. Diabetes damages blood vessels in many organs of the body including the eyes.
More informationUse of Scanning Laser Ophthalmoscope Microperimetry in Clinically Significant Macular Edema in Type 2 Diabetes Mellitus
Use of Scanning Laser Ophthalmoscope Microperimetry in Clinically Significant Macular Edema in Type 2 Diabetes Mellitus Fumihiko Mori, Satoshi Ishiko, Norihiko Kitaya, Taiichi Hikichi, Eiichi Sato, Akira
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationRETINAL CONDITIONS RETINAL CONDITIONS
GENERAL INFORMATION RETINAL CONDITIONS RETINAL CONDITIONS WHAT ARE RETINAL CONDITIONS? Retinal conditions affect the light-sensitive tissue at the back of eye known as the retina. They include diseases
More informationCase Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report Inherent Challenges in Managing Long Standing Refractory Diabetic Macular Edema V Swetha E Jeganathan 1,2 * and Karen Madill 3 1 Department of Ophthalmology,
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationIRIDEX IQ 577 TM Does What Other Lasers Can t. Ahad Mahootchi, MD The Eye Clinic of Florida
IRIDEX IQ 577 TM Does What Other Lasers Can t Ahad Mahootchi, MD The Eye Clinic of Florida IRIDEX IQ 577 One Machine That Treats More Patients More Diseases IRIDEX IQ 577 Safely treats the macula without
More informationCitation BioMed Research International, 2015, v. 2015, article no Creative Commons: Attribution 3.0 Hong Kong License
Title Relationship between Outer Retinal Layers Thickness and Visual Acuity in Diabetic Macular Edema Author(s) Wong, RLM; Lee, JWY; Yau, GSK; Wong, IYH Citation BioMed Research International, 2015, v.
More informationEFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY
EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road
More informationR&M Solutions
Mohamed Hosny El-Bradey, MD., Assistant Professor of Ophthalmology, Tanta University. Wael El Haig, MD., Professor of Ophthalmology. Zagazeeg University. 1 Myopic CNV is considered the most common vision
More informationAdvances in assessing and managing vision impairment
Advances in assessing and managing vision impairment John Grigg Associate Professor and Head Discipline of Ophthalmology Consultant Ophthalmologist Sydney Eye Hospital and The Children s Hospital at Westmead
More informationDiabetic retinopathy (DR) is the leading cause of
LONG-TERM SAFETY, HIGH-RESOLUTION IMAGING, AND TISSUE TEMPERATURE MODELING OF SUBVISIBLE DIODE MICROPULSE PHOTOCOAGULATION FOR RETINOVASCULAR MACULAR EDEMA JEFFREY K. LUTTRULL, MD,* CHRISTOPHER SRAMEK,
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationYear 4 Results For a Phase 1 Trial of Voretigene Neparvovec in Biallelic RPE65- Mediated Inherited Retinal Disease
8:00 AM Year 4 Results For a Phase 1 Trial of Voretigene Neparvovec in Biallelic RPE65- Mediated Inherited Retinal Disease Albert M. Maguire, MD OBJECTIVE Assess maintenance of functional vision/visual
More informationA Review of Subthreshold Micropulse Laser and Recent Advances in Retinal Laser Technology
Ophthalmol Ther (2017) 6:1 6 DOI 10.1007/s40123-017-0077-7 REVIEW A Review of Subthreshold Micropulse Laser and Recent Advances in Retinal Laser Technology Daniel Su. Jean-Pierre Hubschman Received: December
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationCourse C21. Visual Electrophysiology in Children. 12 June, :15-17:45 hrs. Room 118/119 HAND-OUTS
Course C21 Visual Electrophysiology in Children 12 June, 2017 16:15-17:45 hrs Room 118/119 HAND-OUTS Introducing visual electrophysiology tests and results Ruth Hamilton - A description of paeditaric tests
More informationAndrew J. Barkmeier, MD; Benjamin P. Nicholson, MA; Levent Akduman, MD
c l i n i c a l s c i e n c e Effectiveness of Laser Photocoagulation in Clinically Significant Macular Edema With Focal Versus Diffuse Parafoveal Thickening on Optical Coherence Tomography Andrew J. Barkmeier,
More informationVERTEPORFIN IN PHOTODYNAMIC THERAPY STUDY GROUP
Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions With Occult With No Classic Choroidal
More informationThe College of Optometrists - Learning outcomes for the Professional Certificate in Medical Retina
Learning outcomes for the Professional Certificate in Medical Retina, incorporating diabetic retinopathy screening and age related macular degeneration The professional certificate is a prerequisite to
More informationSupplementary Appendix
This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Edwards TL, Jolly JK, MacLaren RE, et al.. N Engl J Med 206;374:996-8. DOI: 0.056/NEJMc50950
More informationOptical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
Columbia International Publishing Journal of Ophthalmic Research (2014) Research Article Optical Coherence Tomograpic Features in Idiopathic Retinitis, Vasculitis, Aneurysms and Neuroretinitis (IRVAN)
More informationOPHTHALMOLOGICAL DISORDERS
Telephone No.: 24622495 Telegraphic Address: Aeronautical: VIDDYAYX Commercial: AIRCIVIL NEW DELHI E Mail: dri@dgca.nic.in Fax:01124629211 GOVERNMENT OF INDIA AERONAUTICAL INFORMATION SERVICE DIRECTOR
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationPreliminary report on effect of retinal panphotocoagulation on rubeosis iridis and
British Journal of Ophthalmology, 1977, 61, 278-284 Preliminary report on effect of retinal panphotocoagulation on rubeosis iridis and neovascular glaucoma LEILA LAATIKAINEN From Moorfields Eye Hospital,
More informationThe Human Eye. Cornea Iris. Pupil. Lens. Retina
The Retina Thin layer of light-sensitive tissue at the back of the eye (the film of the camera). Light rays are focused on the retina then transmitted to the brain. The macula is the very small area in
More informationLong-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized
More informationWidefield Retinal Imaging with Auto Fluorescence Technology in the Optometric Practice
Widefield Retinal Imaging with Auto Fluorescence Technology in the Optometric Practice This course will define ultra-widefield retinal imaging and autofluorescence for the attendee. Will show how it is
More informationYasser R. Serag, MD Tamer Wasfi, MD El- Saied El-Dessoukey, MD Magdi S. Moussa, MD Anselm Kampik, MD
Microperimetric Evaluation of Brilliant Blue G- assisted Internal Limiting Membrane Peeling By Yasser R. Serag, MD Tamer Wasfi, MD El- Saied El-Dessoukey, MD Magdi S. Moussa, MD Anselm Kampik, MD The internal
More informationPhotocoagulation of disciform macular lesions
British Journal of Ophthalmology, 1979, 63, 669-673 Photocoagulation of disciform macular lesions with krypton laser A. C. BIRD AND R. H. B. GREY From the Institute of Ophthalmology, Moorfields Eye Hospital,
More informationWhen optical coherence tomography (OCT)
Macular Imaging: SD-OCT in nterior Segment Surgical Practice Many pathologic processes of the macula can be visualized or quantified only with this modality. y Steven G. Safran, MD When optical coherence
More informationA retrospective nonrandomized study was conducted at 3
Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine 1, Seoul, Korea Hangil Eye Hospital 2, Incheon, Korea Seoul National University Bundang Hospital 3, Seongnam,
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationMicropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: A Randomized Pilot Trial
CLINICAL SCIENCE Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: A Randomized Pilot Trial Luiz Roisman, MD; Fernanda Pedreira Magalhães, MD; Daniel Lavinsky, MD; Nilva Moraes,
More informationSubthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review
274 Current Diabetes Reviews, 2012, 8, 274-284 Subthreshold Diode Micropulse Laser Photocoagulation (SDM) as Invisible Retinal Phototherapy for Diabetic Macular Edema: A Review Jeffrey K. Luttrull 1,*
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationAnswer three questions out of four questions.
Ancillary Material: Nil ACADEMIC UNIT OF OPHTHALMOLOGY & ORTHOPTICS Summer Semester 2016 ELECTRODIAGNOSIS 1 Hour 30 Minutes You are advised to use the 4 leaf answer book. There are four questions. Attempt
More informationSubclinical Diabetic Macular Edema Study
Diabetic Retinopathy Clinical Research Network Subclinical Diabetic Macular Edema Study Version 2.0 March 21, 2006 Subclinical DME Protocol v2 0 3-21-06.doc Table of Contents Chapter 1. Background Information
More informationOCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes
Doc Ophthalmol (2008) 116:159 164 DOI 10.1007/s10633-008-9113-1 CASE REPORT OCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes Hongling Chen Æ Mingzhi Zhang Æ Shizhou
More informationScientists responsible for Endpoint Management (EpM), Topcon s tissuesparing
INSERT TO EpM TISSUE-SPARING LASER THERAPY A DISCUSSION WITH PASCAL EXPERTS MARCH 2018 VOL. 13, NO. 2 SPONSORED BY TOPCON CONTRIBUTING AUTHORS: VICTOR H. GONZALEZ, MD DANIEL PALANKER, PhD EpM TISSUE-SPARING
More informationSubject: Electroretinography
01-92000-28 Original Effective Date: 05/15/15 Reviewed: 03/22/18 Revised: 01/01/19 Subject: Electroretinography THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS,
More informationHHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14.
High-Speed Ultrahigh-Resolution OCT of Bruch s Membrane in Membranoproliferative Glomerulonephritis Type 2 Mehreen Adhi, MD, Sarah P. Read, MD, PhD, Jonathan J. Liu, PhD, James G. Fujimoto, PhD, and Jay
More informationCommon Causes of Vision Loss
Common Causes of Vision Loss Learning Objectives To identify the most common causes of vision loss in the United States To differentiate the most common forms of agerelated macular degeneration and diabetic
More informationOptical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
More informationHydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening
linical Guidelines Hydroxychloroquine and hloroquine Retinopathy: Recommendations on Screening February 2018 - Review date: February 2021 Executive Summary Recent data have highlighted that hydroxychloroquine
More informationDOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος
DOME SHAPED MACULOPATHY Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY-DEFINITIONS The entity Dome Shaped Macula ( DSM ) was first described by Gaucher and associates in 2008
More informationVISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT
The Professional Medical Journal DOI: 10.17957/TPMJ/16.2856 ORIGINAL PROF-2856 VISUAL OUTCOME IN DIABETIC MACULAR EDEMA AFTER GRID LASER TREATMENT 1. MBBS.FCPS Assistant Professor Ophthalmology Independent
More informationVitrectomy for Diabetic Cystoid Macular Edema
Vitrectomy for Diabetic Cystoid Macular Edema Yukihiro Sato, Zeon Lee and Hiroyuki Shimada Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan Purpose: We evaluated visual outcomes
More informationMeasurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography
c l i n i c a l s c i e n c e Measurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography Emily A. McCourt, MD; Brian C. Cadena, PhD; Cullen J. Barnett, CRA; Antonio
More informationRetinal rejuvenation a restorative treatment breakthrough
Retinal rejuvenation a restorative treatment breakthrough AGE-RELATED MACULAR DEGENERATION (AMD) CLINICALLY SIGNIFICANT MACULAR EDEMA (CSME) Helping the world see clearly 2 2RT FROM ELLEX Combating some
More informationElectro Retinogram Basics and Major Clinical Applications
Ophthalmic Instrumentation Electro Retinogram Basics and Major Clinical Applications Meena C K. DNB, Thomas Cherian MS, Elizabeth Chacko BSc Optometry Electroretinogram is the electrical potential generated
More information04/11/2014. Retina Coding and Reimbursement 101. Financial Disclosure. Chief Complaint
Retina Coding and Reimbursement 101 William T. Koch, COA, COE, CPC Administrative Director Director of Billing Operations The Retina Institute St. Louis, Missouri Advisory Boards Allergan Genentech Regeneron
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network An Observational Study of the Development of Diabetic Macular Edema Following Scatter Laser Photocoagulation Version 1.4 June 24, 2005 PRP Obs Study Protocol
More informationLocal Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431)
Local Coverage Determination (LCD): Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI) (L34431) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.
More informationINTRODUCTION. Trans Am Ophthalmol Soc 2010;108:62-76
INTERPRETING THICKNESS CHANGES IN THE DIABETIC MACULA: THE PROBLEM OF SHORT- TERM VARIATION IN OPTICAL COHERENCE TOMOGRAPHY MEASURED MACULAR THICKENING (AN AMERICAN OPHTHALMOLOGICAL SOCIETY THESIS) BY
More informationC horoideraemia is an X linked, recessively inherited,
658 CLINICAL SCIENCE Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia M Flynn Roberts, G A Fishman, D K Roberts, J R Heckenlively, R G Weleber, R J Anderson,
More informationThe Evolution of Fundus Perimetry
The Evolution of Fundus Perimetry Company Profile CenterVue designs and manufactures highly automated medical devices for the diagnosis and management of ocular pathologies, including those that represent
More informationCLINICAL SCIENCES. Consistency Between Visual Acuity Scores Obtained at Different Test Distances
CLINICAL SCIENCES Consistency Between Visual Acuity Scores Obtained at Different Test Distances Theory vs Observations in Multiple Studies Li Ming Dong, PhD; Barbara S. Hawkins, PhD; Marta J. Marsh, MS
More informationDiabetic Retinopathy Clinical Research Network
Diabetic Retinopathy Clinical Research Network Comparison of Time Domain OCT and Spectral Domain OCT Retinal Thickness Measurement in Diabetic Macular Edema Version 1.0 June 16, 2009 comparison of td vs
More informationThe ideal tool for early detection and monitoring of AMD.
The ideal tool for early detection and monitoring of AMD. presenting maia 1 MAIA, the new frontier of Fundus Perimetry (microperimetry) assesses the function of the macula representing an effective clinical
More informationCLINICAL SCIENCES. Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration
CLINICAL SCIENCES Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration Three-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials TAP Report
More informationDiabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the
More informationRETINA 2018 OBJECTIVES OCT VERY USEFUL INFORMATION SAFE AND FRIENDLY 1/11/2018 KELLY MITCHELL
RETINA 2018 KELLY MITCHELL OBJECTIVES HIGHLIGHT NEW DIAGNOSTIC & TREATMENT OPTIONS REVIEW DIAGNOSTIC KEYS OF SELECT RETINAL DISEASES DISCUSS USE OF IMAGING AND REFERRAL RECOURSES FOR PATIENT BENEFIT OCT
More informationA Comparative Study of Age Related Macular Degeneration In Relation To SD-OCTand Fundus Photography.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 11 Ver. III (Nov. 2015), PP 33-37 www.iosrjournals.org A Comparative Study of Age Related Macular
More informationNeovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion
Neovascular Glaucoma Associated with Cilioretinal Artery Occlusion Combined with Perfused Central Retinal Vein Occlusion Man-Seong Seo,* Jae-Moon Woo* and Jeong-Jin Seo *Department of Ophthalmology, Chonnam
More informationDIABETIC RETINOPATHY IS
CLINICAL SCIENCES Agreement of the Heidelberg Retina Tomograph II Macula Edema Module With Fundus Biomicroscopy in Diabetic Maculopathy Mila Kisilevsky, MD; Christopher Hudson, PhD; John G. Flanagan, PhD;
More informationRETINA TODAY. Tissue-sparing Micropulse Diode Laser Photocoagulation in Practice Articles by:
Supplement to Sponsored by Iridex RETINA TODAY April 2011 Tissue-sparing Micropulse Diode Laser Photocoagulation in Practice Articles by: Victor Chong, MD, FRCS, FRCOphth Martin A. Mainster, MD, PhD, FRCOphth
More informationGLAUCOMA SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES
SUMMARY BENCHMARKS FOR PREFERRED PRACTICE PATTERN GUIDELINES Introduction These are summary benchmarks for the Academy s Preferred Practice Pattern (PPP) guidelines. The Preferred Practice Pattern series
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More information